PharmaLifeScience News

...

Draig, a brain drug startup, debuts with $140M to treat depression

The funds will support Phase 2 testing of a drug the company believes to be able to safety home in on AMPA receptors, an emerging but unproven depression target.
READ MORE
...

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already struggled to grow sales.
READ MORE
...

Bristol Myers Squibb to present positive new data on lymphoma treatment

Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory marginal zone lymphoma (MZL). The new data will be presented at the International Conference on Malignant Lymphoma, Lugano, Switzerland, on 19 June, building on data announced in February. Breyanzi
READ MORE